Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
Status:
Completed
Trial end date:
2016-04-22
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of oral
eleclazine and its metabolite, GS-623134, in participants with normal and impaired hepatic
function. Participants in the healthy control group will be matched to participants with
impaired hepatic function by age (± 5 years), gender, and body mass index (± 10%).